<DOC>
	<DOCNO>NCT00967538</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy etanercept patient psoriasis unsatisfactory response adalimumab infliximab .</brief_summary>
	<brief_title>Safety Efficacy Etanercept Patients With Psoriasis Who Failed Respond Other Biologic Treatments</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Patient plaque psoriasis show unsatisfactory response adalimumab . Unsatisfactory response define patient fail reach PGA clear almost clear ( PGA 0 1 ) follow least 12 week adalimumab 40 mg EOW ; OR Patient plaque psoriasis lose his/her satisfactory response adalimumab . Loss satisfactory response define patient treat adalimumab 40 mg EOW least 12 week , achieve PGA clear almost clear ( PGA 0 1 ) lose PGA response ( increase PGA 2 , 3 , 4 5 ) time 12 week adalimumab ; OR Patient plaque psoriasis lose his/her satisfactory response infliximab . Loss satisfactory response define patient treat least 3 infliximab infusion 5 mg/kg , achieve PGA clear almost clear ( PGA 0 1 ) lose PGA response ( increase PGA 2 , 3 , 4 5 ) time 3rd infusion infliximab ; Patient 's age 18 80 year old ; Patient PGA 3 Day 0 ; Patient BSA 3 % Day 0 ; Patient psoriasis severe enough eligible systemic therapy ; Unless surgically sterile ( least 1 year postmenopausal woman ) , abstinent , patient ( male female ) willing use effective method contraception least 30 day Day 0 least 1 month last drug administration ; Patient capable give informed consent ; Patient normal non clinically significant chest Xray within 6 month prior Day 0 ; Patient negative Purified Protein Derivative ( PPD ) Quantiferon TB Gold test within 90 day prior Day 0 ; Female patient childbearing potential negative serum pregnancy test ; Patient able start etanercept per approved product monograph . Patient use topical steroid , topical tar preparation , antipsoriatic preparation within two week prior Day 0 study period , unless patient use topical therapy last 4 week period patient lose satisfactory response adalimumab infliximab patient fail achieve satisfactory response adalimumab ; Patient presence erythrodermic , pustular guttate psoriasis ; Patient significant infection within 30 day prior Day 0 ; Patient receive investigational drug within four week prior screen study period ; Patient treat systemic antipsoriatic drug steroid , retinoids , cyclosporine , PUVA therapy methotrexate within four week prior Day 0 study period ; Patient receive systemic antibiotic within four week prior Day 0 ; Patient treat ultraviolet light therapy ( UVB , nbUVB ) within two week prior Day 0 study period ; Patient use adalimumab infliximab within 14 day Day 0 study period ; Patient use biologic agent treatment psoriasis besides etanercept 8 week prior Day 0 study period ; Patient allergic reaction adalimumab , infliximab etanercept ; Patient unstable serious medical condition define investigator presence significant medical condition might cause study detrimental patient ; Uncontrolled severe comorbidities poorly control diabetes mellitus , NYHA class III IV heart failure , history myocardial infarction cerebrovascular accident transient ischemic attack within three month screen visit ; unstable angina pectoris ; uncontrolled hypertension , oxygendependent severe pulmonary disease ; Patient know seropositivity HIV virus history immunosuppressive disease ; Patient active chronic Hepatitis B C ; Patient mycobacterial disease , patient chest XRay suggestive tuberculosis patient take antituberculosis medication ; Patient know hypersensitivity etanercept one component ; Patient receive live attenuated vaccine within 12 week prior Day 0 plan receive one study ; Current pregnancy lactation ; At investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>etanercept</keyword>
	<keyword>efficacy</keyword>
	<keyword>response</keyword>
	<keyword>anti-TNF alpha</keyword>
	<keyword>treatment efficacy</keyword>
</DOC>